Target Sequencing and Resequencing Market (By Technology: Sequencing, Re-sequencing; By Application: Clinical application, Plant and animal sciences, Drug development, Others; By Type: DNA-based targeted sequencing, RNA-based targeted sequencing; By End-Use: Hospitals & clinics, Academic research, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global target sequencing and resequencing market size was exhibited at USD 5.99 billion in 2022 and is projected to hit around USD 47.75 billion by 2032, growing at a CAGR of 23.07% during the forecast period 2023 to 2032.

target sequencing and resequencing market size

Key Pointers:

  • North American region dominated the market and generated more than 50.4% of the revenue share in 2022.
  • By Technology, the sequencing segment contributed more than 72.7% of revenue share in 2022.
  • By Application, the clinical segment dominated the market in 2022.
  • By Type, the DNA-based segment captured for the maximum market share in 2022. 
  • By End-use, the academic study segment generated more than 50.9% of the revenue share in 2022.

Target Sequencing and Resequencing Market Report Scope

Report Coverage

Details

Market Size in 2023

USD 7.37 Billion

Market Size by 2032

USD 47.75 Billion

Growth Rate From 2023 to 2032

CAGR of 23.07%

Base Year

2022

Forecast Period

2023 to 2032

Segments Covered

By Technology, By Application, By Type, and By End-Use

Market Analysis (Terms Used)

Value (US$ Million/Billion) or (Volume/Units)

Regional Scope

North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa

Key Companies Profiled

Illumina, Inc., Agilent Technologies, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, DNASTAR Inc., Bio-Rad Laboratories, Inc., PacBio, Integrated DNA Technologies, Inc., RainDance Technologies, Inc., Perkin Elmer, Inc., BGI, PierianDx, Genomatix GmbH, GATC Biotech Ag, Macrogen, Inc., QIAGEN, Oxford Nanopore Technologies and Others.

 

The continuous technological developments in genome sequencers along with broad applications and adoption of NGS technology is expected drive the market growth. Furthermore, the increasing application of NGS in molecular diagnostics and precision medicione is also anticipated to create growth opportunities for market growth.

NGS is expected to witness increasing adoption in various disease conditions and infectious disease treatment, along with Noninvasive Prenatal Testing, transplant medicine, and pharmacogenomics. Targeted gene panels and gene expression profiling through qPCR remain the two most common applications for NGS sequencers in a pathology laboratory. While oncology remains a primary area of NGS use in clinics, pathologists are expected to adopt it in other areas too over the coming years. Such factors are expected to boost market growth in the forecast period.

On the other hand, the introduction of novel products is expected to boost targeted sequencing and resequencing market growth. For instance, in October 2022, the Illumina genomics Forum introduced the NovaSeq X, which can run around 20,000 whole genomes a year on one system. This novel system has 10 billion flow cells. When run at 2×150 base pair reads, it will output 6 TB. Moreover, in December 2021, F. Hoffmann-La Roche AG launched the AVENIO Edge System for simplifying the automation of NGS sample preparation and driving advancements in precision medicine. This novel system is a pre-analytical platform that offers end-to-end, integrated, consistently high-quality outcomes.

Key entities in the targeted sequencing & resequencing market are focusing on collaboration to strengthen their market position. For instance, in March 2021, Illumina collaborated with Geneseeq to commercialize and develop IVD NGS kits in China for cancer care. This novel kit was developed by using Illumina’s NextSeq 550Dx sequencing system, which was approved by China’s NMPA (National Medical Products Administration). Moreover, in March 2021, Hackensack Meridian Health and Genomic Testing Cooperative (GTC) entered into a partnership to establish an oncology-focused RNA and DNA sequencing laboratory in the U.S. This lab—Anthology Diagnostics—will perform NGS of cell-free DNA from liquid biopsy samples and DNA/RNA from tumor samples.

Some of the prominent players in the Target Sequencing and Resequencing Market include:

  • Illumina, Inc.
  • Agilent Technologies
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd
  • DNASTAR Inc.
  • Bio-Rad Laboratories, Inc.
  • PacBio
  • Integrated DNA Technologies, Inc.
  • RainDance Technologies, Inc.
  • Perkin Elmer, Inc.
  • BGI
  • PierianDx
  • Genomatix GmbH
  • GATC Biotech Ag
  • Macrogen, Inc.
  • QIAGEN
  • Oxford Nanopore Technologies

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Target Sequencing and Resequencing market.

By Technology

  • Sequencing
  • Re-sequencing
  • Electrophoresis-based resequencing
  • NGS
  • Array-based resequencing

By Application

  • Clinical application
  • Plant and animal sciences
  • Drug development
  • Others

By Type

DNA-based targeted sequencing

RNA-based targeted sequencing

By End-Use

  • Hospitals & clinics
  • Academic research
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Frequently Asked Questions

The global target sequencing and resequencing market size was exhibited at USD 5.99 billion in 2022 and is projected to hit around USD 47.75 billion by 2032

The major players operating in the target sequencing and resequencing market are Illumina, Inc., Agilent Technologies, Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd, DNASTAR Inc., Bio-Rad Laboratories, Inc., PacBio, Integrated DNA Technologies, Inc., RainDance Technologies, Inc., Perkin Elmer, Inc., BGI, PierianDx, Genomatix GmbH, GATC Biotech Ag, Macrogen, Inc., QIAGEN, Oxford Nanopore Technologies and Others.

The driving factors of the target sequencing and resequencing market are the demand for personalised medicine, the rising incidence of genetic disorders, and the expanding uptake of next generation sequencing technology.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Target Sequencing and Resequencing Market 

5.1. COVID-19 Landscape: Target Sequencing and Resequencing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Target Sequencing and Resequencing Market, By Technology

8.1. Target Sequencing and Resequencing Market, by Technology, 2023-2032

8.1.1. Sequencing

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Re-sequencing

8.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Target Sequencing and Resequencing Market, By Application

9.1. Target Sequencing and Resequencing Market, by Application, 2023-2032

9.1.1. Clinical application

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Plant and animal sciences

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Drug development

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Target Sequencing and Resequencing Market, By Type

10.1. Target Sequencing and Resequencing Market, by March, 2023-2032

10.1.1. DNA-based targeted sequencing

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. RNA-based targeted sequencing

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Target Sequencing and Resequencing Market, By End-Use 

11.1. Target Sequencing and Resequencing Market, by End-Use, 2023-2032

11.1.1. Hospitals & clinics

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Academic research

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Others

11.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Target Sequencing and Resequencing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology (2020-2032)

12.1.2. Market Revenue and Forecast, by Application (2020-2032)

12.1.3. Market Revenue and Forecast, by Type(2020-2032)

12.1.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Type(2020-2032)

12.1.5.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Type(2020-2032)

12.1.6.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology (2020-2032)

12.2.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.3. Market Revenue and Forecast, by Type(2020-2032)

12.2.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Type(2020-2032)

12.2.5.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Type(2020-2032)

12.2.6.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Type(2020-2032)

12.2.7.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Application (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Type(2020-2032)

12.2.8.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology (2020-2032)

12.3.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.3. Market Revenue and Forecast, by Type(2020-2032)

12.3.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Type(2020-2032)

12.3.5.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Type(2020-2032)

12.3.6.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Type(2020-2032)

12.3.7.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Application (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Type(2020-2032)

12.3.8.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology (2020-2032)

12.4.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.3. Market Revenue and Forecast, by Type(2020-2032)

12.4.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Type(2020-2032)

12.4.5.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Type(2020-2032)

12.4.6.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Type(2020-2032)

12.4.7.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Application (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Type(2020-2032)

12.4.8.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology (2020-2032)

12.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.5.3. Market Revenue and Forecast, by Type(2020-2032)

12.5.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Application (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Type(2020-2032)

12.5.5.4. Market Revenue and Forecast, by End-Use (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Application (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Type(2020-2032)

12.5.6.4. Market Revenue and Forecast, by End-Use (2020-2032)

Chapter 13. Company Profiles

13.1. Illumina, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Agilent Technologies

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Thermo Fisher Scientific, Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. F. Hoffmann-La Roche Ltd

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. DNASTAR Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Bio-Rad Laboratories, Inc.

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. PacBio

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Integrated DNA Technologies, Inc.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. RainDance Technologies, Inc.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Perkin Elmer, Inc.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers